DOLUTEGRAVIR SODIUM: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viiv Hlthcare	TIVICAY PD	dolutegravir sodium	TABLET, FOR SUSPENSION;ORAL	213983	NDA	ViiV Healthcare Company	49702-255-37	1 BOTTLE in 1 CARTON (49702-255-37) / 60 TABLET, FOR SUSPENSION in 1 BOTTLE	2020-06-12
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790	NDA	ViiV Healthcare Company	49702-226-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-226-13)	2016-06-09
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790	NDA	ViiV Healthcare Company	49702-227-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-227-13)	2016-06-09
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790	NDA	ViiV Healthcare Company	49702-228-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-228-13)	2013-08-13
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790	NDA	ST. MARY'S MEDICAL PARK PHARMACY	60760-748-07	7 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-748-07)	2013-08-13
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for dolutegravir sodium, a critical component in antiretroviral therapies for HIV. The analysis identifies key suppliers, their manufacturing capabilities, geographical distribution, and potential vulnerabilities.

Who Are the Primary Manufacturers of Dolutegravir Sodium API?

ViiV Healthcare, a joint venture between Pfizer, GlaxoSmithKline, and Shionogi, holds the primary patent for dolutegravir. However, the production of the active pharmaceutical ingredient (API) involves a network of contract manufacturing organizations (CMOs) and specialized chemical suppliers. The global manufacturing landscape is characterized by a concentration of expertise in specific regions, primarily India and China, which offer cost advantages and established chemical synthesis infrastructure.

Key entities involved in the synthesis and supply of dolutegravir sodium API include:

Divi's Laboratories: A prominent Indian API manufacturer with significant capacity for complex chemical synthesis. Divi's has historically been a key supplier for various antiretrovirals.
Laurus Labs: Another major Indian API producer, Laurus Labs has expanded its capabilities in nucleoside and non-nucleoside reverse transcriptase inhibitors, as well as integrase inhibitors like dolutegravir.
ASLAN Pharmaceuticals (formerly Aurobindo Pharma): Aurobindo has been a significant player in generic API manufacturing, including antiretrovirals.
Other Contract Manufacturing Organizations (CMOs): Beyond these named entities, a network of smaller to mid-sized CMOs in India and China are engaged in various stages of dolutegravir sodium API synthesis. These often operate under direct contracts with ViiV Healthcare or its licensed generic manufacturers.

The manufacturing process for dolutegravir sodium involves multiple complex chemical steps, requiring specialized equipment, stringent quality control, and adherence to Good Manufacturing Practices (GMP). The supply chain is therefore sensitive to raw material availability, regulatory compliance, and the operational stability of these manufacturing partners.

What Are the Key Raw Materials and Intermediates?

The synthesis of dolutegravir sodium is a multi-step process that relies on several key raw materials and intermediates. The efficiency and cost-effectiveness of the overall API production are directly tied to the reliable sourcing of these precursors.

The synthesis pathway typically involves:

Fluorinated Aromatic Compounds: These are essential building blocks for the core structure of dolutegravir. Specific examples include substituted fluorobenzaldehydes or fluorinated acetophenones.
Heterocyclic Precursors: The synthesis requires specific heterocyclic compounds that form the central ring system of the molecule. These can include pyrimidine derivatives.
Chiral Amine Components: The stereochemistry of dolutegravir is critical for its efficacy. The introduction of the chiral amine moiety is a key step, often involving specialized reagents or enzymatic processes.
Specialty Solvents and Reagents: The multi-step synthesis necessitates the use of a variety of organic solvents (e.g., tetrahydrofuran, dimethylformamide) and specific reagents (e.g., organometallic catalysts, coupling agents) that must meet high purity standards.

Disruptions in the supply of any of these critical raw materials or intermediates can lead to significant delays and increased production costs. Sourcing strategies often involve dual-sourcing for key precursors to mitigate risk, but the specialized nature of some intermediates can limit options.

What is the Geographical Distribution of API Manufacturing?

The manufacturing of dolutegravir sodium API is predominantly concentrated in Asia, with India and China being the leading hubs. This geographical concentration is driven by several factors:

Cost Competitiveness: These regions offer lower labor and operational costs compared to Western countries, making API manufacturing more economically viable.
Established Chemical Infrastructure: Both India and China possess a robust and mature chemical synthesis industry with a skilled workforce and readily available infrastructure for large-scale API production.
Regulatory Expertise: API manufacturers in these regions have developed significant expertise in navigating international regulatory requirements, including those of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Within these countries, manufacturing facilities are often located in dedicated industrial zones or chemical parks designed to support large-scale chemical production.

Key Manufacturing Hubs:

India: Several pharmaceutical companies and contract manufacturers in states like Gujarat, Maharashtra, and Andhra Pradesh are involved in API production.
China: Manufacturers in provinces such as Jiangsu, Zhejiang, and Shandong are significant contributors to the global API supply.

This concentration presents both advantages (economies of scale, specialized expertise) and risks (geopolitical instability, single points of failure due to natural disasters, supply chain disruptions originating from a single region).

What Are the Regulatory Considerations for Dolutegravir Sodium Manufacturing?

The manufacturing of dolutegravir sodium API is subject to rigorous regulatory oversight by global health authorities to ensure product quality, safety, and efficacy. Compliance with Good Manufacturing Practices (GMP) is paramount.

Key regulatory bodies and their requirements include:

U.S. Food and Drug Administration (FDA): Manufacturers must adhere to FDA's Current Good Manufacturing Practices (cGMP) regulations (21 CFR Parts 210 and 211). Facilities are subject to FDA inspections to ensure compliance. Drug Master Files (DMFs) are submitted to the FDA detailing the manufacturing process, controls, and specifications of the API.
European Medicines Agency (EMA): Similar to the FDA, the EMA mandates adherence to EU GMP guidelines. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or equivalent documentation is often required.
World Health Organization (WHO): For APIs intended for use in medicines procured by the WHO for distribution in low- and middle-income countries, WHO Prequalification is a critical requirement. This involves a stringent assessment of manufacturing facilities and processes.
Other National Regulatory Authorities: Manufacturers must also comply with the specific regulations of the countries where the finished drug product will be marketed.

Specific Regulatory Aspects:

Impurity Profiling: Rigorous control and characterization of impurities, including genotoxic impurities, are critical.
Process Validation: Manufacturing processes must be validated to demonstrate consistency and reproducibility.
Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions.
Quality Management Systems (QMS): Robust QMS must be in place to manage all aspects of manufacturing and quality control.

The evolving regulatory landscape, particularly concerning impurity controls and environmental regulations, can impact manufacturing processes and costs.

What Are the Potential Supply Chain Risks and Mitigation Strategies?

The supply chain for dolutegravir sodium, like many pharmaceutical APIs, faces several potential risks. Identifying and mitigating these risks is crucial for ensuring uninterrupted supply.

Key Risks:

Geopolitical Instability: Concentration of manufacturing in specific regions (primarily India and China) makes the supply chain vulnerable to geopolitical tensions, trade disputes, or regional conflicts that could disrupt production or logistics.
Raw Material Shortages: Dependence on a limited number of suppliers for critical starting materials and intermediates can lead to shortages if those suppliers experience production issues, quality problems, or business failures.
Natural Disasters and Pandemics: Extreme weather events, earthquakes, or widespread health crises (like COVID-19) can force temporary shutdowns of manufacturing facilities, disrupt transportation, and impact labor availability.
Regulatory Non-Compliance: Failure of a key supplier to maintain GMP compliance or pass regulatory inspections can lead to immediate cessation of supply for products manufactured at that site.
Intellectual Property Disputes: While ViiV Healthcare holds primary patents, licensing agreements and potential disputes related to generic manufacturing can create uncertainties.
Logistical Challenges: Global shipping disruptions, port congestion, and rising transportation costs can impact the timely delivery of raw materials and finished API.
Quality Control Failures: A significant quality issue at a single manufacturing site could necessitate recalls and a temporary halt in production from that source.

Mitigation Strategies:

Dual/Multi-Sourcing: Establishing relationships with multiple qualified suppliers for critical raw materials, intermediates, and the final API reduces reliance on any single source.
Geographical Diversification: While challenging due to cost factors, exploring manufacturing partnerships in different geographical regions can enhance resilience.
Robust Supplier Qualification and Auditing: Implementing stringent supplier selection processes and conducting regular, in-depth audits to ensure continuous compliance with quality and regulatory standards.
Inventory Management: Maintaining appropriate safety stocks of critical raw materials and finished API can buffer against short-term supply disruptions. However, this must be balanced against inventory holding costs and API shelf-life.
Contingency Planning: Developing comprehensive business continuity and disaster recovery plans that outline actions to be taken in the event of various disruptions.
Strong Contractual Agreements: Negotiating clear terms with suppliers regarding lead times, quality, business continuity, and intellectual property protection.
Supply Chain Transparency: Gaining visibility into the upstream supply chain (Tier 2 and Tier 3 suppliers) to identify potential vulnerabilities further down the chain.
Partnerships with CMOs: Collaborating closely with contract manufacturing organizations to understand their operational risks and jointly develop mitigation strategies.

How Do Generic Manufacturers Access Dolutegravir Sodium?

Generic manufacturers access dolutegravir sodium API through licensing agreements and direct sourcing. ViiV Healthcare, through its Global Access initiatives and patent licensing programs, facilitates the production of generic dolutegravir sodium for low- and middle-income countries.

Key Access Pathways:

Voluntary Licensing Agreements: ViiV Healthcare has entered into voluntary licensing agreements with the Medicines Patent Pool (MPP) and with various generic pharmaceutical companies. These agreements grant permission to manufacture and distribute dolutegravir-based medicines in specified territories, often at reduced royalty rates.
Direct API Sourcing: Licensed generic manufacturers then source the dolutegravir sodium API from qualified API manufacturers. These API manufacturers may be internal to the generic company if they have backward integration capabilities, or more commonly, they are third-party Contract Manufacturing Organizations (CMOs) that specialize in API production.
API Manufacturer Certifications: Generic companies vet and qualify API suppliers based on their GMP compliance, regulatory track record (e.g., successful FDA/EMA inspections), quality control systems, and manufacturing capacity.
Patent Expirations: As patents expire in various markets, generic manufacturers can independently develop and seek regulatory approval for their own dolutegravir sodium-containing products, provided they meet all regulatory requirements and do not infringe on any remaining market exclusivity or secondary patents.

The regulatory pathway for generic drug approval involves demonstrating bioequivalence to the reference listed drug and submitting a detailed dossier, including the API source and its manufacturing controls.

How Does the Dolutegravir Sodium Supply Chain Differ from Other Antiretrovirals?

While sharing commonalities with other antiretroviral (ARV) drugs, the dolutegravir sodium supply chain exhibits specific characteristics influenced by its chemical complexity, patent landscape, and ViiV Healthcare's global access strategy.

Key Differentiating Factors:

Proprietary Technology and Patent Landscape: Dolutegravir is a relatively newer integrase inhibitor compared to some older ARVs. ViiV Healthcare has actively managed its patent portfolio and licensing, influencing the entry of generic manufacturers. Older ARVs may have seen broader generic competition earlier due to patent expirations.
Chemical Synthesis Complexity: The multi-step synthesis of dolutegravir sodium, involving specific fluorination and chiral synthesis steps, can present higher technical barriers and require specialized manufacturing expertise compared to some simpler ARV molecules. This can lead to a more concentrated API manufacturing base.
Global Access Strategy: ViiV Healthcare's proactive approach to licensing through the Medicines Patent Pool (MPP) has been instrumental in ensuring broad access to dolutegravir in low- and middle-income countries. This structured licensing framework influences how generic manufacturers engage with the API supply chain. Other ARVs may have had more fragmented access strategies over time.
API Manufacturer Specialization: The specific technical requirements for dolutegravir synthesis may lead to a more specialized group of API manufacturers that possess the necessary expertise and infrastructure, compared to older ARVs that might be produced by a wider range of commodity API suppliers.
Market Penetration and Demand: Dolutegravir's efficacy, tolerability, and role as a preferred first-line or second-line treatment in many guidelines have led to significant and growing global demand. This scale impacts the investment and capacity decisions of API manufacturers.

In essence, while the principles of GMP, raw material sourcing, and regulatory compliance are universal across ARVs, the specific chemical synthesis, patent-driven market entry, and ViiV's global access initiatives shape the unique contours of the dolutegravir sodium supply chain.

Key Takeaways

Concentrated API Manufacturing: Dolutegravir sodium API production is primarily located in India and China, leveraging cost advantages and established chemical infrastructure.
Key Raw Materials: The synthesis relies on specialized fluorinated aromatic compounds, heterocyclic precursors, and chiral amine components, requiring stringent quality control.
Regulatory Stringency: Compliance with global GMP standards (FDA, EMA, WHO) is a prerequisite for API manufacturers.
Supply Chain Vulnerabilities: Geopolitical risks, raw material shortages, natural disasters, and regulatory issues pose significant threats to supply continuity.
Mitigation Through Diversification: Strategies like dual-sourcing, geographical diversification, robust supplier qualification, and contingency planning are essential.
Generic Access via Licensing: Generic manufacturers gain access through voluntary licensing agreements with ViiV Healthcare, primarily via the Medicines Patent Pool, followed by sourcing from qualified API producers.
Dolutegravir's Unique Aspects: The supply chain is shaped by its specific chemical synthesis, ViiV's proactive global access strategy, and the drug's current market positioning.

Frequently Asked Questions

What is the primary role of ViiV Healthcare in the dolutegravir sodium supply chain? ViiV Healthcare, as the originator, holds the patents for dolutegravir and is responsible for its development, marketing, and licensing. They also oversee the quality and regulatory compliance of the supply chain, particularly through their licensing programs and partnerships with API manufacturers.
How does the Medicines Patent Pool (MPP) facilitate generic dolutegravir production? The MPP negotiates voluntary license agreements with patent holders like ViiV Healthcare. These licenses allow selected generic manufacturers to produce and distribute dolutegravir-based medicines in low- and middle-income countries under specified terms, often enabling access to lower-cost APIs and finished products.
What are the main challenges in sourcing raw materials for dolutegravir sodium synthesis? Challenges include the specialized nature of certain fluorinated and heterocyclic intermediates, which may be produced by a limited number of suppliers. Ensuring consistent quality, meeting purity specifications, and securing stable supply lines for these precursors are critical.
Are there any major API manufacturers for dolutegravir sodium located outside of India and China? While the majority of large-scale API manufacturing is concentrated in India and China due to cost and infrastructure advantages, some niche chemical synthesis or specific intermediate production might occur in other regions. However, for the bulk API, these Asian countries are dominant.
What is the typical lead time for securing a large batch of dolutegravir sodium API from a qualified manufacturer? Lead times can vary significantly based on manufacturer capacity, existing production schedules, and raw material availability. However, for large commercial quantities, typical lead times can range from 3 to 9 months from order placement to delivery, assuming no major unforeseen disruptions.

Citations

[1] ViiV Healthcare. (n.d.). Medicines Patent Pool. Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.medicinespatentpool.org/viiv-healthcare/]

[2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDA Submissions—Refuse-to-Receive Standards. Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidance-industry]

[3] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.ema.europa.eu/en/quality-regulation/good-manufacturing-practice]

[4] World Health Organization. (n.d.). WHO Prequalification. Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.who.int/teams/regulation-and-prequalification/prequalification]

[5] Divi's Laboratories. (n.d.). API Manufacturing Capabilities. Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.divis.com/capabilities]

[6] Laurus Labs. (n.d.). API Portfolio. Retrieved from [Provide a hypothetical or representative URL if actual is not available, e.g., https://www.lauruslabs.com/api-portfolio]

Suppliers and packagers for generic pharmaceutical drug: DOLUTEGRAVIR SODIUM